The purpose of this study is to find the genes that increase the risk of developing an ischemic stroke using DNA samples collected from concordant (stroke-affected) sibling pairs.

Condition
Stroke

Further Study Details: 

Expected Total Enrollment:  900

Stroke is the third leading cause of death in the United States and a leading cause of acquired disability in adults. Each year, about 700,000 people experience stroke in the country. Ischemic stroke, which constitutes about 80 percent of all strokes, is a complex genetic disorder--the result of interactions between multiple genes and multiple environmental exposures. Genes affecting cholesterol, blood pressure, clotting, and other factors may increase the risk of ischemic stroke.

In this clinical study, investigators are studying groups of siblings in which at least two of the siblings have had an ischemic stroke. The goal of this multi-center study is to find the genes that increase the risk of developing an ischemic stroke.

To accomplish the aims of the study, researchers are using DNA samples collected from concordant (stroke-affected) sibling pairs to determine if there are regions in the human genome associated with ischemic stroke or that may harbor stroke susceptibility genes.

Two teaspoons of blood will be collected from each participant and submitted for genetic analysis. Understanding the genetic predisposition to stroke could have major benefits for public health.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Subject diagnosed by a study neurologist as having had a symptomatic ischemic stroke in the past.
• Head Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) done within 7 days of symptom onset confirms absence of etiology other than ischemic stroke.
• Subject reports having at least one living sibling with a stroke.
• Subject is 18 years of age or older.

Exclusion Criteria:

• The index ischemic stroke occurred within 48 hours after a cardiovascular or cerebrovascular procedure.
• The index ischemic stroke occurred within 60 days after a non-traumatic subarachnoid hemorrhage.
• The subject has brain biopsy-proven central nervous system vasculitis.
• The subject is known to have any one of the following genetic disorders: CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), Fabry's disease, homocystinuria, MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, Stroke), or sickle cell anemia.
• The subject has a mechanical aortic valve or mechanical mitral valve.
• The subject had untreated or actively treated bacterial endocarditis at the time of the index ischemic stroke.

Please refer to this study by ClinicalTrials.gov identifier  NCT00108940

Alexa Skarp      904-953-7839 

Alabama
      University of South Alabama, Mobile,  Alabama,  36617,  United States; Recruiting
California
      East Bay Region Assoc., Berkeley,  California,  94705,  United States; Recruiting
      Scripps Clinic, La Jolla,  California,  92039,  United States; Recruiting
      Mercy General Hospital, Sacramento,  California,  95819,  United States; Recruiting
Connecticut
      Yale University, New Haven,  Connecticut,  06520-8018,  United States; Recruiting
Florida
      Mayo Clinic College of Medicine Jacksonville, Jacksonville,  Florida,  32224,  United States; Recruiting
      Shands Jacksonville, Jacksonville,  Florida,  32209,  United States; Recruiting
      Florida Neurovascular Institute, Tampa,  Florida,  33606,  United States; Recruiting
      Cleveland Clinic - Florida, Weston,  Florida,  33331,  United States; Recruiting
Indiana
      Indiana University/Clarian Health Partners, Indianapolis,  Indiana,  46202,  United States; Recruiting
Maine
      Maine Medical Center, Scarborough,  Maine,  04074,  United States; Recruiting
Maryland
      University of Maryland, Baltimore,  Maryland,  21201,  United States; Recruiting
Minnesota
      Mayo Clinic, Rochester,  Minnesota,  55905,  United States; Recruiting
New York
      Helen Hayes Hospital, West Haverstraw,  New York,  10994,  United States; Recruiting
North Carolina
      Wake Forest University School of Medicine, Winston Salem,  North Carolina,  27157,  United States; Recruiting
Ohio
      Metro Health, Cleveland,  Ohio,  44109,  United States; Recruiting
      University of Cincinnati, Cincinnati,  Ohio,  45267-0525,  United States; Recruiting
      Ohio State University, Columbus,  Ohio,  43210,  United States; Recruiting
Pennsylvania
      Thomas Jefferson University Hospital, Philadelphia,  Pennsylvania,  19107,  United States; Recruiting
      University of Penn. Med. Center, Philadelphia,  Pennsylvania,  19104,  United States; Recruiting
Virginia
      University of Virginia, Charlottesville,  Virginia,  22908,  United States; Recruiting
Wisconsin
      Luther Midelfort Clinic, Eau Claire,  Wisconsin,  54703,  United States; Recruiting
      University of Wisconsin, Madison, Madison,  Wisconsin,  53792,  United States; Recruiting
Canada, Ontario
      Stroke Prevention and Atherosclerosis Research Centre, Siebens-Drake Research Institute, London,  Ontario,  N6G 2V2,  Canada; Recruiting
Canada, Quebec
      Hospital Charles Le Moyne, Greenfield Park,  Quebec,  J4V2H1,  Canada; Recruiting

Study chairs or principal investigators

James F. Meschia, M.D.,  Principal Investigator,  Mayo Clinic College of Medicine Jacksonville   

Study ID Numbers:  R01NS39987
Record last reviewed:  April 2005
Last Updated:  April 22, 2005
Record first received:  April 20, 2005
ClinicalTrials.gov Identifier:  NCT00108940
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-05-03